Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Nalani Hunsaker

Physician Assistant, Medical Escondido, CA Physician Assistant

NPI 1144769886 CMS profile 10901204

625 W. Citracado Pkwy, #112, Escondido, CA 92025

Open in the dashboard

General payments

$38,808

161 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Nalani Hunsaker of Escondido, CA is reported in the CMS Open Payments database as having received $38,808 across 161 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14 1
2024 General $6,516 21
2023 General $23,557 77
2022 General $4,009 23
2021 General $4,712 39

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Nalani Hunsaker
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Nalani Hunsaker were reported at $14. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Nalani Hunsaker Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $4,712 $156 $41–$563 $132
2022 $4,009 $185 $55–$649 $149
2023 $23,557 $199 $58–$717 $160
2024 $6,516 $206 $62–$740 $164
2025 $14 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $38,038 119 payments
  2. Xeris Pharmaceuticals, Inc. $120 6 payments
  3. Insulet Corporation $106 5 payments
  4. Tandem Diabetes Care, Inc. $103 4 payments
  5. Lilly USA, LLC $103 5 payments
  6. AstraZeneca Pharmaceuticals LP $91 5 payments
  7. Abbott Laboratories $62 8 payments
  8. Nevro Corp. $32 1 payment
  9. AbbVie, Inc. $29 2 payments
  10. Relypsa, Inc. $24 1 payment
  11. Other $100 5 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $24,579 24 payments
  2. Travel and Lodging $10,356 39 payments
  3. Food and Beverage $2,512 95 payments
  4. Consulting Fee $1,360 2 payments
  5. Education $1 1 payment
Products named General payments · program years 2021–2025
  1. INTELLIS ADAPTIVESTIM $23,485 71 payments
  2. MINIMED 780G $5,396 14 payments
  3. Minimed 770G System $2,566 5 payments
  4. InPen $1,142 3 payments
  5. INPEN SMART INSULIN DELIVERY SYSTEM $873 2 payments
  6. Omnipod $106 5 payments
  7. FARXIGA $91 5 payments
  8. GVOKE PFS $77 4 payments
  9. BAQSIMI $68 3 payments
  10. t-slim insulin pump $58 2 payments
  11. Other $488 30 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 17 drugs

Part D claims

430

Median for Physician Assistant: 241

Drug cost

$344,212

Median for Physician Assistant: $4,110

Branded share of claims

90.2%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 106 $128,203
Mounjaro Tirzepatide Brand 42 $56,292
Rybelsus Semaglutide Brand 40 $50,601
Farxiga Dapagliflozin Propanediol Brand 29 $22,826
Trulicity Dulaglutide Brand 22 $22,778
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 14 $19,783
Jardiance Empagliflozin Brand 22 $19,652
Gvoke Hypopen 2-Pack Glucagon Brand 19 $12,070
Novolog Flexpen Insulin Aspart Brand 15 $3,684
Humalog Insulin Lispro Brand 11 $2,657

The 10 drugs with the highest cost, of 17 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 8 billing codes

Paid by Medicare

$10,800

Medicare's payments for the services billed

Medicare patients

54

Average age 75

Services billed

191

35 women, 19 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Diabetes 75%
High blood pressure 75%
Chronic kidney disease 59%
Arthritis 26%
Heart failure 20%
Ischemic heart disease 20%
Alzheimer's or dementia 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

161 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record